Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Metabolexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biolexis Therapeutics Launches Subsidiary Metabolexis to Develop Novel Oral Medicines for Obesity and Type 2 Diabetes to Improve Human Longevity","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Clarke Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Biolexis Therapeutics

    Menu

    Biolexis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Biolexis Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development

              Details:

              The new funding will advance Biolexis' development pipeline which includes a range of promising metabolic drug candidates, including MLX0800, oral small molecules for the treatment of obesity and type 2 diabetes.

              Lead Product(s): MLX0800

              Therapeutic Area: Nutrition and Weight Loss Product Name: MLX0800

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Clarke Capital

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing November 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Biolexis Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Biolexis Therapeutics Launches Subsidiary Metabolexis to Develop Novel Oral Medicines for Obesity and Type 2 Diabetes to Improve Human Longevity

              Details:

              MLX7000 is a oral small molecules, which is trageted as Glucagon-like peptide-1 receptor, which is investigated for the treatment of weight loss and type 2 diabetic.

              Lead Product(s): MLX7000

              Therapeutic Area: Nutrition and Weight Loss Product Name: MLX7000

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Metabolexis

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY